Niki BioSolutions, Inc. NIKI
Industrial Machinery/Components · IPO 2018 · data as of November 13, 2026
Niki BioSolutions, Inc. (NIKI) is a industrial company listed in the US with a market value of about $5M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -55%.
About Niki BioSolutions
Niki BioSolutions is listed in the US and classified in industrial machinery/components, IPO year 2018. It was profitable in 1 of the last 8 years in our data.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $431378 | $1M | $2M | — | — | — |
| Net income | -$1M | -$4M | -$3M | -$10M | -$25M | $5M | -$20M | -$15M |
| Free cash flow | — | — | -$8M | -$13M | -$15M | -$16M | -$14M | -$16M |
| EPS (diluted) | $-0.46 | $-1.45 | $-0.96 | $-3.33 | $-8.52 | $1.67 | $-6.85 | $-5.05 |
| Net margin | — | — | -654.8% | -756.2% | -1624.6% | — | — | — |
| ROIC | — | — | -30.1% | -72.1% | -63.0% | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Niki BioSolutions pay a dividend?
Not currently.
Is Niki BioSolutions a good stock to buy?
We do not give buy or sell advice. Niki BioSolutions scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.